title: Coexisting dysbetalipoproteinemia and familial hypercholesterolemia. Clinical and laboratory observations.
abstract: Type III dysbetalipoproteinemia and familial hypercholesterolemia (FH) are two metabolic disorders giving rise to severe disturbances of lipid homeostasis and premature atherosclerosis. Both metabolic abnormalities have a genetic basis and co-occurrence in the same patient has seldom been described. Because of the unique structure of the French Canadian population, there was an opportunity to observe patients with both dysbetalipoproteinemia (E2/2 homozygotes) and FH (N=14) and to compare their clinical data with that of patients with type III (N=75), patients with FH (N0.7 and the presence of beta-VLDL on electrophoresis. Presence of a low density lipoprotein receptor, LDL-R, mutation should be suspected in a type III patient with a LDL-C level above 3.0 mmol/l and a family history of premature CAD. In the group of patients studied, the coexistence of dysbetalipoproteinemia and heterozygous FH does not appear to increase the prevalence of cardiovascular complications above that observed among control type III or control E3/3-FH patients. Thus, the presence of two epsilon2 alleles in these patients affects the expression of the abnormal LDL-R allele and the resulting phenotype substantiates the non additive effects of alleles at these two loci (epistasis).
authors.affiliation: Endocrine Service, Hospital Clinico Universitario, Valencia, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Carmena
authors.forename: M
authors.initials: M
authors.lastname: Roy
authors.forename: G
authors.initials: G
authors.lastname: Roederer
authors.forename: A
authors.initials: A
authors.lastname: Minnich
authors.forename: J
authors.initials: J
authors.lastname: Davignon
mesh_terms: D000328:Adult; D000368:Aged; D000483:Alleles; D053329:Apolipoprotein E2; D001057:Apolipoproteins E / Q000235:genetics; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology; D002340:Carotid Artery Diseases / Q000453:epidemiology / Q000209:etiology; D008078:Cholesterol, LDL / Q000097:blood; D005260:Female; D006579:Heterozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009154:Mutation; D010641:Phenotype; D015995:Prevalence; D011973:Receptors, LDL / Q000097:blood; D012016:Reference Values
chemical_list: D053329:Apolipoprotein E2; D001057:Apolipoproteins E; D008078:Cholesterol, LDL; D011973:Receptors, LDL